AsclepiX Therapeutics

Our Pipeline

Our lead product is AXT107, with additional follow on product candidates AXT201, AXT301 and AXT501. Our initial therapeutic focus for AXT107 is on diabetic macular edema (DME), age-related macular degeneration (wet AMD), and macular edema following retinal vein occlusion (RVO), which are the leading causes of blindness in the western world. AXT201, AXT301 and AXT501 are in early development for the treatment of a variety of solid tumors.

Our Pipeline

Our lead product is AXT107, with additional product candidates AXT201, AXT301 and AXT501.

Product CandidatesProgram AreaPreclinicalPhase 1Phase 2/3

Ophthalmology

AXT107

Diabetic Macular Edema

wet AMD

Retinal Vein Occlusion

Oncology

AXT201

Triple-Negative Breast Cancer

Solid Tumor

Oncology

AXT301, AXT501

Solid Tumor

Early Research

Early Pipeline

Various Indications

AXT107

AXT107 is a synthetic 20-mer collagen IV‑derived peptide. It has demonstrated efficacy in 10 different animal models of retinal disease. Our initial therapeutic focus is on diabetic macular edema (DME), age-related macular degeneration (wet AMD), and macular edema following retinal vein occlusion (RVO), which are the leading causes of blindness in the western world.

AXT107 inhibits VEGFR2 and activates Tie2, the two prominent pathways for the treatment of retinal vascular diseases. The peptide has the unique potential to be dosed possibly only once yearly, compared with every 1 to 3 months as is required for currently approved products and those in clinical development for the treatment of DME, wet AMD or RVO.

Product CandidatesProgram AreaPreclinicalPhase 1Phase 2/3

Ophthalmology

AXT107

Diabetic Macular Edema

Wet AMD

Retinal Vein Occlusion

AXT201

AXT201 is a 20-mer collagen IV-derived peptide being developed to treat solid tumors such as triple negative breast cancer (TNBC).  AXT201 inhibits tumor growth, improves survival, and promotes anti-tumor immunity in TNBC models.

AXT201 is another peptide derived from the noncollagenous domain of collagen IV and is being developed for the treatment of solid tumors. On its own, AXT201 has demonstrated potent tumor growth inhibition in aggressive mouse tumor models of triple-negative breast cancer by targeting the tumor vascular and immune microenvironment. By inhibiting new vascular growth, stabilizing existing blood vessels and inhibiting lymphatic vessel growth, AXT201 is able to block the growth and metastatic progression, or spreading, of the cancer to different organs while also enhancing the delivery of other therapies into the tumor. In addition, the molecule can alter tumor immune regulating signals. thereby increasing the susceptibility of the tumor to the host’s immune response. Together, these effects of AXT201 can be combined with current standards of care, such as chemotherapy or immunotherapy, to both improve their delivery and efficacy.

Oncology

AXT201

Triple-Negative Breast Cancer

Solid Tumor

AXT301 and AXT501

AXT301 and AXT501 are other product candidates that are also currently under investigation for the treatment of solid tumors and other various indications.

AXT301 is a 24-mer CXC chemokine-derived peptide being developed to treat solid tumors. AXT301 inhibits tumor growth in orthotopic TNBC and glioma models.

AXT501 is a 14-mer somatotropin-derived peptide being developed to treat solid tumors. AXT501 inhibits tumor growth in orthotopic TNBC models.

Product CandidatesProgram AreaPreclinicalPhase 1Phase 2/3

Oncology

ATX301, ATX501

Solid Tumor

Product CandidatesProgram AreaPreclinicalPhase 1Phase 2/3

Early Research

Early Pipeline

Various Indications

Diabetic macular edema (DME)

Diabetic macular edema (DME) is an accumulation of fluid in the macula which is the central portion of the retina that is responsible for central, high-resolution, color vision. DME can occur in individuals with either Type 1 or Type 2 diabetes, and it is a consequence of poorly controlled blood glucose that contributes to changes in the small vessels in the retina–a condition called diabetic retinopathy. Left untreated, diabetic retinopathy lead to blood or fluid accumulation on the retina, as well as causing swelling (edema) of the macula.

Diabetic eye disease is a leading cause of avoidable blindness worldwide, accounting for about 2.6% of all cases of global blindness. DME, which affects about 2 million Americans: about 10% of people with diabetes and about 70% of those with the most severe form of diabetic retinopathy, is known to contribute greatly to this vision loss.

Several known risk factors are known to contribute to the development of DME, including the length of time living with diabetes, unregulated blood glucose levels, poor diet, and history of cardiovascular disease.

Macular Edema Following Retinal Vein Occlusion (RVO)

Retinal vein occlusion (RVO) occurs when the flow of blood from the retina is blocked. Based on the location of the blockage, RVO can be categorized into branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO), with BRVO occurring more commonly than CRVO.

Macular edema is the major complication causing the central vision loss in patients with BRVO or CRVO. Macular edema arises from breakdown of the blood retinal barrier at the capillary endothelium, resulting in the leakage of fluids into the retina, which causes blurring or loss of vision.

RVO is the second most common sight threatening retinal vascular disorder after diabetic retinopathy. Globally, an estimated 28.1 million adults are affected by RVO (4.7million by CRVO and 23.4 million by BRVO). Advanced age, hypertension, heart attack history, stroke history, higher level of total cholesterol and higher level of creatinine were risk factors for RVO.